Skip to main content
Erschienen in: Acta Neuropathologica 6/2012

01.06.2012 | Original Paper

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

verfasst von: Felix Sahm, Christian Koelsche, Jochen Meyer, Stefan Pusch, Kerstin Lindenberg, Wolf Mueller, Christel Herold-Mende, Andreas von Deimling, Christian Hartmann

Erschienen in: Acta Neuropathologica | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

CIC and FUBP1 mutations have recently been detected in oligodendrogliomas but not in oligoastrocytomas. However, allelic losses in the regions on chromosomal arms 19q and 1p harboring CIC and FUBP1 are a common feature of both, oligodendrogliomas and oligoastrocytomas. To resolve this discrepancy, we analyzed CIC and FUBP1 mutations in a set of primary brain tumors including 18 oligodendrogliomas and 42 oligoastrocytomas. In addition, we analyzed 10 astrocytomas and 16 glioblastomas with allelic losses on 19q as well as a set of 12 medulloblastomas for CIC mutations. CIC mutations were found in 15/18 oligodendrogliomas, 14/42 oligoastrocytomas and 3/10 preselected astrocytomas. With the exception of a single case, all CIC mutations occurred in tumors with combined 1p/19q losses. In contrast to oligodendrogliomas where CIC mutations were always detected along with 1p/19q co-deletion, CIC mutations were only found in 52 % of the 1p/19q co-deleted oligoastrocytomas. FUBP1 mutations were detected in 7/61 tumors, all presenting with CIC mutations. FUBP1 mutations appear to cluster in the DNA binding domain spanning exons 5–14. CIC and FUBP1 mutations exclusively occurred in presence of either IDH1 or IDH2 mutations. Our data confirm CIC and FUBP1 mutations in oligodendrogliomas and demonstrate the presence of these mutations in oligoastrocytomas.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602PubMedCrossRef Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602PubMedCrossRef
2.
Zurück zum Zitat Bender B, Wiestler OD, von Deimling A (1994) A device for processing large acrylamide gels. Biotechniques 16:204–206PubMed Bender B, Wiestler OD, von Deimling A (1994) A device for processing large acrylamide gels. Biotechniques 16:204–206PubMed
3.
Zurück zum Zitat Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455PubMedCrossRef Bettegowda C, Agrawal N, Jiao Y et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455PubMedCrossRef
4.
Zurück zum Zitat Duncan R, Bazar L, Michelotti G et al (1994) A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8:465–480PubMedCrossRef Duncan R, Bazar L, Michelotti G et al (1994) A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 8:465–480PubMedCrossRef
5.
Zurück zum Zitat Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474PubMedCrossRef Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474PubMedCrossRef
6.
Zurück zum Zitat Kim Y, Andreu MJ, Lim B et al (2011) Gene regulation by MAPK substrate competition. Dev Cell 20:880–887PubMedCrossRef Kim Y, Andreu MJ, Lim B et al (2011) Gene regulation by MAPK substrate competition. Dev Cell 20:880–887PubMedCrossRef
7.
Zurück zum Zitat Lee CJ, Chan WI, Cheung M et al (2002) CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol Brain Res 106:151–156PubMedCrossRef Lee CJ, Chan WI, Cheung M et al (2002) CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res Mol Brain Res 106:151–156PubMedCrossRef
8.
Zurück zum Zitat Lee CJ, Chan WI, Scotting PJ (2005) CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol 73:101–108PubMedCrossRef Lee CJ, Chan WI, Scotting PJ (2005) CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas. J Neurooncol 73:101–108PubMedCrossRef
9.
Zurück zum Zitat Louis D, Ohgaki H, Wiestler O et al (2007) World Health Organization Classification of Tumours of the Central Nervous System. In: Bosman F, Jaffe E, Lakhani S et al (eds) World Health Organization Classification of Tumours, 4th edn. IARC, Lyon Louis D, Ohgaki H, Wiestler O et al (2007) World Health Organization Classification of Tumours of the Central Nervous System. In: Bosman F, Jaffe E, Lakhani S et al (eds) World Health Organization Classification of Tumours, 4th edn. IARC, Lyon
10.
Zurück zum Zitat Malz M, Weber A, Singer S et al (2009) Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50:1130–1139PubMedCrossRef Malz M, Weber A, Singer S et al (2009) Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50:1130–1139PubMedCrossRef
11.
Zurück zum Zitat Parsons DW, Li M, Zhang X et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331:435–439PubMedCrossRef Parsons DW, Li M, Zhang X et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331:435–439PubMedCrossRef
12.
Zurück zum Zitat Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML et al (2009) Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50:1121–1129PubMedCrossRef Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML et al (2009) Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50:1121–1129PubMedCrossRef
13.
Zurück zum Zitat Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937PubMedCrossRef Weller M, Berger H, Hartmann C et al (2007) Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937PubMedCrossRef
14.
Zurück zum Zitat Yip S, Butterfield YS, Morozova O et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7–16PubMedCrossRef Yip S, Butterfield YS, Morozova O et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226:7–16PubMedCrossRef
Metadaten
Titel
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
verfasst von
Felix Sahm
Christian Koelsche
Jochen Meyer
Stefan Pusch
Kerstin Lindenberg
Wolf Mueller
Christel Herold-Mende
Andreas von Deimling
Christian Hartmann
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 6/2012
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-012-0993-5

Weitere Artikel der Ausgabe 6/2012

Acta Neuropathologica 6/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.